

1 **Immunosenescence profile is associated with increased susceptibility to severe**  
2 **COVID-19**

3 Lucas Haniel A. Ventura<sup>1#</sup>, Lícia Torres<sup>1#</sup>, Giovanna Caliman Camatta<sup>1</sup>, Jofer  
4 Zamame<sup>2</sup>, Monique Macedo Coelho<sup>1</sup>, Cecília Horta Ramalho-Pinto<sup>1</sup>, João Gervazio<sup>1</sup>,  
5 Felipe Caixeta<sup>1</sup>, Leandro Nascimento<sup>1</sup>, Mariana Almeida Oliveira<sup>1</sup>, Vinícius Dantas  
6 Martins<sup>1</sup>, Marcos Felipe Oliveira<sup>1</sup>, Murilo Soares da Costa<sup>3</sup>, Hugo Itaru Sato<sup>1</sup>, Henrique  
7 Cerqueira Guimarães<sup>4</sup>, Rafael Calvão Barbuto<sup>4</sup>, Ana Paula Rocha Veiga<sup>5</sup>, Najara  
8 Ataíde<sup>5</sup>, Gabriela Prandi Caetano<sup>5</sup>, Sarah Rangon<sup>5</sup>, Mauro Lúcio O. Júnior<sup>6</sup>, Fernanda  
9 Calvo Fortes<sup>1</sup>, Luciana Zuccherato<sup>1</sup>, Elaine Speziali<sup>7,8</sup>, Olindo Assis Martins-Filho<sup>7</sup>,  
10 Verônica Coelho<sup>9</sup>, Roberto Avritchir<sup>10</sup>, Rafael Souza<sup>5</sup>, Marina Ayupe<sup>2</sup>, Caio Loureiro<sup>2</sup>,  
11 Maria Eduarda Passos<sup>11</sup>, Ana Clara Mota Neves<sup>11</sup>, Pauline Leite<sup>11</sup>, Santuza Maria  
12 Ribeiro Teixeira<sup>1</sup>, Unai Tupinambas<sup>3</sup>, Liza Figueiredo Felicori<sup>1</sup>, Gabriela Silveira-  
13 Nunes<sup>11</sup>, Tatiani Uceli Maioli<sup>1,12</sup>, Denise Morais Fonseca<sup>2</sup>, Andrea Teixeira-Carvalho<sup>7</sup>,  
14 Ana Maria Caetano Faria<sup>1\*</sup>

15

16 <sup>1</sup> Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de  
17 Minas Gerais, Belo Horizonte, Brazil

18 <sup>2</sup> Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Brazil

19 <sup>3</sup> Departamento de Doenças Tropicais e Infecciosas, Faculdade de Medicina, Universidade Federal de  
20 Minas Gerais, Belo Horizonte, Brazil

21 <sup>4</sup> Hospital Risoleta Tolentino Neves, Belo Horizonte, Brazil.

22 <sup>5</sup> Instituto de Infectologia do Hospital Emílio Ribas, São Paulo, Brazil.

23 <sup>6</sup> Hospital da UNIMED, Governador Valadares, Brazil

24 <sup>7</sup> Instituto de Pesquisa René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil

25 <sup>8</sup> Universidade Edson Antônio Velano, Fundação de Ensino e Tecnologia de Alfenas, Belo Horizonte,  
26 Brazil.

27 <sup>9</sup> Instituto do Coração, Universidade de São Paulo, São Paulo, Brazil.

28 <sup>10</sup> Santa Casa de Misericórdia, São Paulo, Brazil.

29 <sup>11</sup> Departamento de Medicina, Universidade Federal de Juiz de Fora, Governador Valadares, Brazil

30 <sup>12</sup> Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo  
31 Horizonte, Brazil

32

33 # These authors contributed equally to this study.

34 \***Corresponding Author:** Ana Maria Caetano Faria, Departamento de Bioquímica e Imunologia,  
35 Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo  
36 Horizonte, CEP 31270-901, MG, Brazil. E-mail: [anacaetanofaria@gmail.com](mailto:anacaetanofaria@gmail.com)

37

38 **Key words:** Immunosenescence, Inflammaging, COVID-19, Immunoglobulin  
39 repertoire, T cell senescence, T cell exhaustion, epigenetic clock

40

41 **Abstract:**

42 In this study we tested the hypothesis that the immunosenescence profile could account  
43 for the disproportional susceptibility of the elderly to severe forms of COVID-19. The  
44 immunological profiles of volunteers residing in endemic and non-endemic areas for  
45 chronic infectious diseases were analyzed at early stage of SARS-CoV-2 infection. A  
46 unique signature of inflammatory plasma mediators was identified in COVID-19  
47 volunteers when compared to individuals with other flu-like syndromes. COVID-19  
48 severity correlated with high levels of inflammatory mediators; among them, CXCL9, a  
49 serum marker of aging. Patients who progressed to hospitalization displayed high  
50 frequencies of CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing exhaustion and senescence markers  
51 and showed reduced and more mature B cell repertoires, which are typical of  
52 senescence. They also had an acceleration of epigenetic age measured by DNA  
53 methylation. Therefore, severe COVID-19 correlated with phenotypic, functional, and  
54 epigenetic features of accelerated immunosenescence at onset of infection.

55 **Introduction:**

56

57 Since the onset of COVID-19 cases, the elderly have been the main risk group  
58 for severe disease worldwide. This pattern of susceptibility was reported initially in  
59 China<sup>1</sup>, Italy<sup>2</sup> and later in several countries including Brazil<sup>3</sup>.

60 SARS-CoV-2 infection is cleared by a normal anti-viral response in most  
61 individuals, but some progress to a hyperinflammatory condition, often with severe  
62 pulmonary involvement. It has been shown that 5–6% of these patients need mechanical  
63 ventilation due to respiratory failure developed by lung and microcirculation damage,  
64 with profound hypoxia, severe acute respiratory syndrome (SARS) and multiple organ  
65 dysfunction. These individuals have systemic hyperinflammation with classical serum  
66 biomarkers of “cytokine storm syndrome” including abnormal coagulation, elevated C  
67 reactive protein (CRP), LDH, ferritin, IL-1 $\beta$ , TNF, IL-6, IFN- $\gamma$ , IL-10, IL-15, IL-2, IL-  
68 5, CCL2, CCL3, CCL4 and CXCL10<sup>4</sup>. Therefore, uncontrolled inflammation is clearly  
69 associated with severe life-threatening COVID-19. Interestingly, many of these  
70 mediators are the ones found to induce a low-grade chronic state of inflammation  
71 known as inflammaging and originated from senescent cells, cumulative stimulation of  
72 immune cells and lifestyle risk factors<sup>5,6</sup>.

73 Aging affects all body compartments, but the immune system is particularly  
74 impacted. Immunosenescence is associated with a decline in the production and activity  
75 of T and B cells, many defects in innate immune cells, and thymic atrophy. The  
76 progressive reduction in the output of naïve T cells from the thymus creates an  
77 oligoclonal repertoire of expanded subsets of memory T cells and exhausted/senescent  
78 lymphocytes (mostly CD8 T cells) with low proliferative capacity. At the same time,  
79 senescent immune and non-immune cells develop a secretory phenotype (SASP) that  
80 includes innate cytokines and chemokines such as CXCL8, IL-6, IL-18, TNF and IL-1 $\beta$   
81 responsible for the development of the inflammaging<sup>6</sup>. Immunosenescence is also  
82 associated with a reduction in production of B cells by the bone marrow. This decline in  
83 T/B cell production leads to the peripheral accumulation of cells with an exhausted  
84 repertoire displaying lower diversity of T/B cell receptors<sup>7,8</sup>, and poor responses to  
85 infectious agents and vaccines<sup>6,9,10</sup>. Thus, response to a virus infection such as SARS-  
86 CoV-2 in the elderly can be very abnormal as already observed for other viruses<sup>11</sup>.

87 Interestingly, not all elderly developed the severe form of COVID-19<sup>12</sup> and not  
88 all aged individuals have a dysfunctional immunological profile. Studies on healthy  
89 nonagenarians and centenarians in Italy and on healthy elderly people in Brazil showed  
90 that these individuals develop remodelling mechanisms to control the deleterious effects  
91 of inflammation and immunosenescence<sup>6,13-15</sup>. On the other hand, our group have  
92 shown that individuals living in endemic areas for infectious diseases (such as  
93 Schistosomiasis, Leishmaniasis, Leprosy, Chagas Disease, Dengue, Chikungunya,  
94 Yellow Fever) exhibit an accelerated biological age as measured by DNA methylation<sup>16</sup>  
95 with an unique immunological profile<sup>14,17-20</sup>. Therefore, aging does not affect  
96 individuals homogeneously and the resulting senescence phenotype seems to be  
97 determined by genetic, epigenetic and biographical factors related to the interactions of  
98 the immune system and the body with its environment.

99 Our hypothesis in this study is that the immunosenescence profile, rather than  
100 the chronological age, will impact on the development of the inflammatory damage seen  
101 in severe COVID-19 by creating a permissive environment for a dysfunctional response  
102 to the virus. Moreover, it is likely that factors such as chronic antigenic exposure in  
103 endemic areas for infectious diseases would enhance a preexisting immunosenescence  
104 phenotype.

105 Although some authors have theoretically proposed an association between  
106 COVID-19 severity and senescence biomarkers such as inflammaging, biological  
107 clocks, mTOR activity, and telomer shortening<sup>21-24</sup>, only few studies have  
108 experimentally addressed this proposal using only cohorts of hospitalized individuals at  
109 heterogeneous time points of infection with mixed results<sup>25,26</sup>.

110 Several distinctive parameters were used in this study to reach non-ambiguous  
111 conclusions when testing our hypothesis: (i) we investigated individuals from three  
112 cities in Brazil with distinct patterns of biological aging; (ii) our cohort had only  
113 individuals at early stage of infection (1-4 days of symptoms) to avoid confusion  
114 between the impact of immunosenescence in COVID-19 outcome with accelerated  
115 immunosenescence induced by SARS-CoV-2 infection itself<sup>27</sup>; (iii) a group of  
116 individuals with flu-like symptoms but negative for SARS-CoV-2 infection was  
117 included as a control to distinguish COVID-19 from other airway viral infections; (iv)  
118 all individuals were clinically followed for 14 days to monitor disease progression,  
119 sometimes from mild to severe, as in the case of a specific group of patients

120 (progression group); (v) four parameters were tested to make up the immunosenescence  
121 profile - plasma mediators to examine the inflammaging, phenotypical biomarkers of  
122 memory, exhaustion and senescence in T cells, diversity and maturity of B cell  
123 repertoires and the epigenetic age of the individuals.

124

## 125 **Results**

126

### 127 **Severe COVID-19 associated with a high inflammatory profile at early stage of** 128 **infection.**

129 The main features of our study population are shown in **Table 1** and **2**. For all  
130 the analysis reported below, individuals in each group were matched by age, sex and  
131 number of comorbidities. We only included in the analysis individuals at early stage of  
132 infection (1-4 days of symptoms). Other factors that could interfere with the  
133 interpretation of our data were also controlled. (i) There was no significant difference in  
134 the body mass index (BMI) among the groups that could contribute as an inflammatory  
135 stimulus to the distinct outcomes <sup>28</sup>. (ii) The presence of comorbidities was a general  
136 feature of our cohort, and the most reported ones were hypertension, diabetes mellitus,  
137 and respiratory diseases. Since they are inflammatory conditions that could interfere  
138 with COVID-19 severity <sup>29</sup>, all groups analysed in this study were matched by the  
139 presence of an equal number of comorbidities (considered as equivalent conditions).  
140 (iii) To exclude the possibility that disease outcome would be related to differences in  
141 viral load as already reported for other infections by virus such as influenza <sup>30</sup> and  
142 adenovirus <sup>31</sup>, concentration values for SARS-CoV-2 ribonucleic acid in each swab  
143 sample were calculate and compared among clinical groups. We used cycle threshold  
144 (Ct) values as a surrogate for viral load given the already reported linear correlation  
145 between Ct values and viral concentration down to the limit of detection<sup>32</sup>.  
146 **Supplementary Figure 1a** shows that individuals with mild, moderate, and severe  
147 COVID-19 presented comparable CT values indicating that disease outcome was not  
148 due to the abundance of virus in the respiratory tract. (iv) Individuals previously  
149 infected by SARS-CoV-2 were identified by serology (using Bio-Plex Multiplex SARS-  
150 CoV-2 Serology Assay Kit) and excluded from the study. (v) Since a high prevalence of  
151 Vitamin D deficiency has been reported to correlate with increased morbidity and  
152 mortality related to COVID-19 infection <sup>33</sup>, serum levels of vitamin D were measured in

153 individuals of our cohort. No significant difference among the clinical groups of  
154 COVID-19 was observed (**Supplementary Figure 1b**) ruling out the possible influence  
155 of its deficiency in the outcome of the disease.

156 Since previous studies have shown that inflammaging is a hallmark of  
157 immunosenescence<sup>10</sup>, we first characterized the inflammatory profile of the individuals  
158 in all groups using a Luminex-Multiplex assay for 27 immune mediators. For this first  
159 analysis, the study population was segregated into five groups: Flu-like Syndrome  
160 (FLS) group comprising individuals who were negative for SARS-CoV-2 and had an  
161 unknown mild respiratory infection, Mild, Moderate and Severe COVID-19 groups  
162 according to WHO classification guidelines<sup>34</sup> (**Supplementary Table 1**). The fifth  
163 group (Progression) consisted of individuals who were classified as Mild COVID-19 at  
164 recruitment but progressed to severe disease with hospitalization during the 14-day  
165 follow-up period.

166 A radar chart showing a global analysis of plasma mediators produced by  
167 individuals with mild, moderate, and severe COVID-19 shows that, at early stage of  
168 infection, disease severity was already positively correlated with the frequency of high  
169 producers of several inflammatory mediators (**Figure 1a**). Among these mediators, we  
170 identified 10 that were significantly different among the groups (**Figure 1b**): CCL2,  
171 CXCL8, CXCL10, IL-1 $\beta$ , IL-6, TNF, IFN-gamma, IL-12p70, IL-1Ra, IL-10. These are  
172 classical inflammatory mediators that are part of the inflammaging phenotype<sup>10,35</sup> and  
173 were already reported to be at high levels in hospitalized COVID-19 patients.  
174 Interestingly, the same list of mediators was also significantly higher in individuals with  
175 mild COVID-19 when compared to the ones with flu-like syndrome (**Figure 1b**).  
176 Although individuals from these two groups shared a spectrum of symptoms and could  
177 only be segregated after RT-PCR testing for SARS-CoV-2 infection, they had a distinct  
178 inflammatory profile. Mild COVID-19 patients presented a higher global pattern of  
179 mediator production (**Figure 1c**) and several differences in the concentrations of the 10  
180 mediators (**Figure 1d, Supplementary Figure 2c**) since early infection. We also  
181 observed differences in this inflammatory profile at other time points of disease  
182 progression with higher immune activation in mild COVID-19 patients when compared  
183 to FLS patients with 5-9 and 10-14 days of symptoms (**Supplementary Figure 2 d, e**).  
184 Probably at this stage, immune mediators resulting from the response to infection are at  
185 play. Therefore, COVID-19 seems to be related to a unique inflammatory profile when

186 compared to other respiratory viral infections with similar symptoms. Notably, when  
187 patients with mild COVID-19 were segregated into adults and elderly, a higher global  
188 profile of inflammatory immune activation was detected in aged individuals  
189 (**Supplementary Figure 2b, e**) during early stages of infection (1-4 days of symptoms)  
190 and later (10-14 days of symptoms) suggesting that inflammaging and the innate  
191 immune response triggered by COVID-19 indeed overlap later when immunity to  
192 infection is established.

193 To help distinguishing between pre-existing inflammaging as a fuel to disease  
194 progression and the viral-induced cytokine storm, we studied an important group of  
195 patients found in our cohort: the progression group. These individuals were classified as  
196 having mild symptoms of COVID-19 when they were recruited (1-4 days of symptoms)  
197 but progressed to severe disease and hospitalization during the 14-day-follow-up period.  
198 Notably, the overall inflammatory profile of these patients represented by a radar plot  
199 (**Figure 1e**) and the comparative analysis of the 10 main plasma mediators (**Figure 1f**)  
200 clearly showed that they presented, since the early stages of infection, an inflammatory  
201 activation similar to the group of severe COVID-19 patients, and significantly different  
202 from Mild and FLS patients. This suggests that the initial immunological imprint of  
203 inflammatory mediators can predict disease outcome.

204

205 **Severe COVID-19 was associated with higher inflammatory activation in**  
206 **individuals from endemic areas for infectious diseases and with biomarkers of**  
207 **aging.**

208 To address the question of how distinct environments influence COVID-19 and  
209 whether aging biomarkers can be used to distinguish the different clinical forms of  
210 disease, we compared the inflammatory profile of adult and elderly individuals with FS  
211 or mild COVID-19 from Belo Horizonte and Governador Valadares, an endemic area  
212 for several infectious diseases where individuals present an accelerated biological aging  
213 <sup>16</sup>. First, we confirmed that there was a clear difference in the global inflammatory  
214 profiles between individuals with FLS and Mild COVID-19 in the endemic area despite  
215 their similarity of symptoms (**Figure 2c**). Moreover, individuals from Governador  
216 Valadares had a higher activation profile when compared to individuals from Belo  
217 Horizonte, and the elderly from the endemic area presented a much higher production of

218 immune mediators than adults (**Figure 2c**). Hence, not only does COVID-19 presented  
219 itself as a greater challenge to the immune system than other respiratory infections, but  
220 the inflammatory activation at early phase of infection is exacerbated in populations  
221 with accelerated biological age.

222 CXCL9 has been recently identified as critical mediator involved in age-related  
223 chronic inflammation<sup>36</sup>. Indeed, using this chemokine as a biomarker of aging and  
224 frailty, we observed that elderly individuals were higher producers of CXCL9 than  
225 adults. Interestingly, both adults and elderly hospitalized patients had a similar and  
226 more prominent production of this mediator than individuals with FLS or mild COVID-  
227 19 (**Figure 2d**). Moreover, elderly individuals presented no difference in CXCL9  
228 production across the spectrum of COVID-19 clinical forms (**Figure 2e**) probably  
229 because they already had high baseline levels of this chemokine. Therefore, severe  
230 COVID-19 was associated at early stage of infection with increased production of an  
231 immunological biomarker of aging.

232 Our data on the inflammatory profile of individuals from endemic and non-  
233 endemic areas in Brazil suggest a strong and unique association between inflammaging  
234 at early stages of COVID-19 to disease progression.

235

236 **Severe COVID-19 correlated with accumulation of memory, exhausted and**  
237 **senescent T cells.**

238 To further explore the association between other features of immunosenescence  
239 and COVID-19 outcomes, we investigated changes in the frequencies of T cell  
240 populations expressing cell markers of memory, exhaustion, and senescence.

241 Aging has a great impact in the T cell compartment, especially in CD8<sup>+</sup> T cells  
242<sup>37</sup>. To investigate variations in the frequencies of functional subsets of T lymphocytes,  
243 multiparametric flow cytometry analyses was performed using a panel of monoclonal  
244 antibodies to surface markers of exhaustion/senescence in these cells (**Supplementary**  
245 **Table 2**). Gating strategies for all cell populations are shown in **Supplementary Figure**  
246 **3**.

247 To investigate immunophenotypes of T lymphocytes, CD4<sup>+</sup> and CD8<sup>+</sup> T cells  
248 were studied as global main subpopulations and segregated into functional subsets of



249 naïve (CD45RO<sup>-</sup>CCR7<sup>+</sup>), effector (CD45RO<sup>-</sup>CCR7<sup>-</sup>), central memory  
250 (CD45RO<sup>+</sup>CCR7<sup>+</sup>), effector memory (CD45RO<sup>+</sup>CCR7<sup>-</sup>) T cells. We identify  
251 accumulation of several subsets of CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing markers of  
252 exhaustion and senescence in patients with severe COVID-19 (**Figure 3**). Concerning  
253 CD8<sup>+</sup> T cell analysis, individuals with severe disease had higher frequencies of CD8<sup>+</sup> T  
254 cells expressing biomarkers of senescence (TIGIT) and exhaustion (ICOS). Effector  
255 CD8<sup>+</sup> T cells expressing PD-1 were also augmented in severe diseased patients (**Figure**  
256 **3 a, b**). In addition, CD8<sup>+</sup> T cells with senescence/ exhaustion phenotypes accumulate in  
257 individuals of this group: CD28<sup>-</sup>PD-1<sup>+</sup>CD57<sup>+</sup>CD8<sup>+</sup>, CD28<sup>+</sup>KLRG1<sup>+</sup>CD8<sup>+</sup>, CD28<sup>-</sup>PD-  
258 1<sup>+</sup>CD8<sup>+</sup>, CD28<sup>-</sup>KLRG1<sup>+</sup> PD-1<sup>+</sup> CD8<sup>+</sup>, KLRG1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup>, KLRG1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup>,  
259 TIGIT<sup>+</sup>ICOS<sup>+</sup> CD8<sup>+</sup> and CD28<sup>-</sup>PD-1<sup>+</sup> effector and effector memory CD8<sup>+</sup> T cells  
260 (**Figure 3 c, d**). For CD4<sup>+</sup> T cells, we also found higher frequencies of cells expressing  
261 the senescence marker TIGIT and of cells expressing the mixed senescence/exhaustion  
262 phenotype: TIGIT<sup>+</sup>ICOS<sup>+</sup>CD4<sup>+</sup>, CD28<sup>-</sup>CD57<sup>+</sup>KLRG1<sup>+</sup>CD4<sup>+</sup> and CD28<sup>-</sup>CD57<sup>+</sup>KLRG1<sup>+</sup>  
263 effector memory CD4<sup>+</sup> T cells (**Figure 3e, f**). For some specific sub-populations of  
264 senescent (CD4<sup>+</sup>TIGIT<sup>+</sup>) (**Figure 3e**) and senescent/exhausted (CD28<sup>-</sup>PD-1<sup>+</sup> effector  
265 and effector memory CD8<sup>+</sup>, TIGIT<sup>+</sup>ICOS<sup>+</sup>CD4<sup>+</sup>) T cells (**Figure 3c**), a significant  
266 difference between patients with mild and moderate disease was observed. Therefore,  
267 along with an exuberant inflammaging, COVID-19 patients exhibited an accrual of  
268 senescent/exhausted CD8<sup>+</sup> and CD4<sup>+</sup> T cells that make up the scenario of dysfunctional  
269 immunity permissive to disease progression.

270

271 **Severity of COVID-19 was associated with a reduction in B cell diversity and**  
272 **higher maturation of the immunoglobulin repertoire.**

273 To study the B cell senescence, we examined the immunoglobulin repertoire in a  
274 set of 45 individuals from individuals in Belo Horizonte and Governador Valadares  
275 (endemic area) who were either uninfected or tested positive for COVID-19. Within  
276 these cities, participants were categorized into negative group (n=6), mild COVID-19  
277 group (n=19), and hospitalized COVID-19 group (n=20) of individuals from Belo  
278 Horizonte and São Paulo along with mild COVID-19 individuals from Governador  
279 Valadares. The sequencing resulted in 285,341 to 1,525,890 raw reads. After pre-  
280 processing, 130,060 to 548,060 annotated reads and 3,053 to 69,737 clones were  
281 obtained (**Supplementary Table 3**).

282 Antibody repertoire diversity within the top 100 most expanded clones among  
283 individuals in Belo Horizonte showed that the Shannon entropy diversity was lower in  
284 the hospitalized individuals as compared to both mild COVID-19 and control groups  
285 (**Figure 4b**). **Figure 4c** also shows that hospitalized individuals had a more mature  
286 repertoire with highly mutated VH immunoglobulin genes and lower frequencies of  
287 germline-encoded antibodies, a phenotype of an aged repertoire. A graphical  
288 representation of clonal expansion at day 2 and 7 of symptom onset shows that in both  
289 periods the clones from severe individuals are distinct from baseline (negative) and  
290 clones from mild individuals (**Figure 4a**).

291

### 292 **Acceleration of biological age was detected in hospitalized individuals with** 293 **moderate/severe COVID-19**

294 To further explore our hypothesis, we accessed the DNA methylation status of  
295 peripheral blood mononuclear cells to investigate whether COVID-19 severity was  
296 associated with acceleration of biological age. We used the cohort of individuals that  
297 had been already investigated for the inflammatory and phenotypic lymphoid profiles  
298 and performed the analysis using different biological age acceleration clocks<sup>16,38</sup>.

299 For this analysis, a negative population was selected as a control. Individuals in  
300 this group had no symptoms of infection and were negative for SARS-CoV-2 by RT-  
301 PCR (**Table 1**). Negative individuals were compared to infected patients with Mild  
302 COVID-19 and a Hospitalized COVID-19 group of patients with either moderate or  
303 severe clinical disease. Several clocks are now available to assess aging acceleration  
304 using different gene clusters. We used seven clocks proposed by Horvath<sup>38</sup>, Horvath  
305 Updated, Levine<sup>39</sup>, Hannum<sup>40</sup>, TL<sup>41</sup>, BLUP, EN, Wu<sup>25,42</sup>, to obtain more accuracy in  
306 detecting acceleration or deceleration of biological age.

307 Based on data previously published by our group showing that the population of  
308 Governador Valadares presents an acceleration of biological age<sup>16</sup>, we decided not to  
309 use these individuals in the initial analysis, so that we could focus on understanding the  
310 association between age acceleration and disease severity (**Figure 4D**). Notably,  
311 individuals of the hospitalized group had an increase in biological age when compared  
312 to the mild COVID-19 group (in Horvath (Updated), Levine, EN, BLUP and TL  
313 watches) and to the negative group (in Horvath, Horvath (Updated), Hannum, BLUP

314 and EN watches) (**Figure 4D**). The Wu clock was the only one of the analysed watches  
315 that showed no difference among groups. Next, we analyzed the total population,  
316 including individuals from Governador Valadares, and the result was similar (**Figure**  
317 **4E**) except for the TL clock that showed no difference among groups.

318 Network analysis is a powerful tool for understanding the complex relationships  
319 between variables within a system. By constructing a network representation, we can  
320 visualize and analyze the interconnections between different components. In our study,  
321 we employed a weighted network analysis to investigate the correlations between  
322 biologically relevant markers associated with cytokines/chemokines and cellular  
323 proteins that are markers of senescence and exhaustion. Individuals who developed  
324 severe COVID-19 had a more connected senescence/exhaustion network than  
325 individuals that developed mild COVID-19 (**Figure 4F**). Among the more connected  
326 clusters, senescent and exhausted T cells are dominant. A graphical representation of all  
327 data obtained on the senescence profile illustrates the general conclusion that patients  
328 with severe disease resemble the aging phenotype (**Figure 4G**).

329 Therefore, our data clearly correlate several features of the immunosenescence  
330 profile including inflammaging, increased frequencies of senescent/exhausted T cells,  
331 oligoclonality of B cell repertoire and finally an acceleration of biological age  
332 suggesting that this dysfunctional immune profile can explain, at least in part, the high  
333 susceptibility of aged people to develop severe forms of COVID-19.

334

## 335 **Discussion**

336 Since the beginning of the SARS-CoV-2 pandemic, the elderly have been the  
337 main risk group for the mortality and the severe clinical outcomes of COVID-19 <sup>2</sup>.  
338 Several review articles have proposed that remodelling features acquired by the aging  
339 immune system such as the inflammaging phenomenon and dysfunctional immunity  
340 might have a major role in the unfavourable outcome of the disease in older individuals  
341 <sup>4,21–24,43</sup>. Besides these theoretical proposals, some studies have addressed the  
342 hypothesis in experiments using senolytics in aged mice infected with a SARS-CoV-2–  
343 related virus<sup>44</sup> and in individuals with severe and critically ill COVID-19 patients by  
344 analyzing exhausted/senescent T cells <sup>45,46</sup> and age-acceleration clocks <sup>25</sup>.

345 In our study, we used more than one approach to reach a reliable conclusion  
346 when testing our hypothesis, we distinguish patients with mild disease from those  
347 severely ill to investigate the effect of aging phenotype in the disease outcome and we  
348 specifically restrict our sample to early infected patients (1-4 days of symptoms), a  
349 period when senescent and exhausted T cells are at baseline frequencies (a small  
350 percentage of the overall cell population) in mild COVID-19<sup>27</sup>. Our group and others  
351 have shown that SARS-CoV-2 infection induces not only a systemic inflammatory  
352 response similar to the inflammaging<sup>47</sup> but it also leads to the emergence of exhausted  
353 and senescent T cells after a period of infection as short as 7 days<sup>27,45</sup>. In addition, we  
354 included volunteers with mild flu-like symptoms who tested negative for SARS-CoV-2  
355 as a control since these individuals did not show accumulation of exhausted/senescent  
356 cells even after 7 days of infection. At this stage, there is probably an overlap between  
357 inflammaging and innate cytokines/ chemokines produced in the early response to  
358 SARS-CoV-2<sup>47</sup> because these two responses share a set of mediators including IL-6,  
359 CXCL8, C-Reactive Protein (CRP), TNF, IL-1 $\beta$ , IL-10, IL-1Ra IL-12p70, IFN- $\gamma$ <sup>6,10</sup>.

360 Ten mediators were consistently identified in all COVID-19 patients with 1-4  
361 days of symptoms, and they were detected at variable levels depending on the clinical  
362 form of the disease. Most of them are proinflammatory mediators (CCL2, CXCL8,  
363 CXCL10, IL-1 $\beta$ , IL-6, TNF, IFN- $\gamma$ , IL-12p70) that contribute to both frailty in the  
364 elderly<sup>10,36,48</sup> and to a series of pathological events seen in COVID-19 such as  
365 thrombosis of blood capillaries, congestion of the alveolar wall, inflammatory  
366 infiltration, formation of hyaline membrane in the alveoli, pulmonary edema, and severe  
367 respiratory failure<sup>5,49</sup> whereas others play an anti-inflammatory and regulatory role (IL-  
368 1Ra and IL-10) in both conditions. Interestingly, even though other viral infections can  
369 induce a burst of innate cytokines/chemokines during the first few days of infection<sup>47</sup>,  
370 the inflammatory signature observed in individuals with mild COVID-19 and Flu-like  
371 syndrome in our study were not equivalent (**Figure 1c, d, Supplementary Figure 1**).  
372 This finding underscores the uniqueness of SARS-CoV-2 infection and suggests that the  
373 overlap between innate response to the virus and the pre-existing inflammaging  
374 phenomenon is of particular importance to COVID-19 with predictive value for the  
375 outcome of the disease. A further demonstration of that is the data collected from  
376 individuals in the Progression group (**Figure 1e, f**) that clearly showed an inflammatory  
377 signature of severe disease at early stages of infection when symptoms are still mild.

378 Another distinctive feature of our study population was the inclusion of a group  
379 of patients from an endemic region for infectious diseases in Brazil (Governador  
380 Valadares, MG). This group allowed us to examine the impact of accelerated  
381 immunosenescence and other changes favourable to the senescence process <sup>16,18</sup> in  
382 COVID-19 development. Indeed, we found a more prominent inflammatory profile in  
383 patients from the endemic area even in the mild COVID-19 and flu-like syndrome  
384 groups and this hyperactivation was exacerbated in the elderly (**Figure 2 a-c,**  
385 **Supplementary Figure 1**). These set of results highlight two important aspects  
386 concerning infectious diseases. First, it demonstrated that there is a variability of  
387 immune responses to a single pathogen, even for those with the same spectrum of  
388 symptoms, and this may be determined by genetic and environmental conditions as  
389 previously proposed <sup>50</sup>. In addition, it suggests that individuals living in areas of high  
390 antigenic burden, despite their accelerated senescence profile <sup>16</sup>, may also develop  
391 mechanisms of inflammatory remodelling resembling the ones observed in centenarian  
392 populations of Italy <sup>6,48</sup> and aged populations in Brazil <sup>17,37</sup>. These mechanisms would  
393 allow them to successfully cope with life-threatening infectious disease such as  
394 COVID-19.

395 Several age clocks based on different biological parameters have been proposed  
396 <sup>38-40,42</sup> and a recent study developed an inflammatory clock (iAge) based on patterns of  
397 systemic age-related inflammation tagged to multimorbidity and frailty in the elderly <sup>36</sup>.  
398 The strongest contributor to iAge was CXCL9, a chemokine involved in cardiac aging  
399 and impaired vascular function. Interestingly, CXCL9 is analogous to and from the  
400 same family of CXCL10, a mediator highly associated with severity of COVID-19 <sup>51</sup>  
401 (**Figures 1 and 2**). CXCL9 was found at high levels in hospitalized (**Figure 2d**),  
402 severely diseased (**Figure 2e, f**) patients and in the elderly from Belo Horizonte and  
403 Governador Valadares regardless of their infection status (**Figure 2d**). Therefore, at  
404 early stage of infection, severe COVID-19 could be distinguished from other clinical  
405 forms of the disease by a strong biomarker of aging.

406 Alongside with the inflammaging phenomena, immunosenescence is marked by  
407 several changes in innate and acquired immunity being lymphocytes and the T cell  
408 compartment the most affect ones. During aging, thymic atrophy, sustained replicative  
409 pressure due to homeostatic proliferation and clonal expansion after antigenic  
410 stimulation leads to the emergence of terminally differentiated T cells such as exhausted

411 and senescent cells. Although these T cell populations share common features such as  
412 functional remodelling and cell cycle arrest, they have also distinctive characteristics <sup>52</sup>.  
413 Chronically stimulated T cells during aging, persistent viral infections and cancer  
414 trigger an exhausted profile characterized by the expression of inhibitory receptors such  
415 as programmed cell death protein 1 (PD-1) <sup>53,54</sup>, inducible costimulatory molecule  
416 (ICOS) <sup>53,54</sup> and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory  
417 motif domain (TIGIT) <sup>55</sup>. Exhausted T cells display a dysfunctional and non-  
418 proliferative state that is reversible. On the other hand, immune and non-immune  
419 senescent cells present a non-reversible loss of their proliferative capacity and acquire a  
420 senescence associated secretory phenotype (SASP) that contributes to inflammaging <sup>56</sup>.  
421 Expression of CD57 <sup>56</sup> and killer cell lectin-like receptor G subfamily member 1  
422 (KLRG1) <sup>56</sup> as well as the loss of the co-stimulatory molecule CD28<sup>56</sup> are considered  
423 indicators of terminal differentiation and are associated with the senescence profile of T  
424 lymphocytes. Although KLRG1 also emerges on the cell surface after differentiation,  
425 the signalling generated by this molecule regulates a pathway related to exhaustion,  
426 making it a marker of both cellular senescence and exhaustion <sup>56</sup>.

427 Notably, we also detected, in patients with severe COVID-19, an accrual of  
428 CD8<sup>+</sup> T cells expressing markers of senescence (TIGIT) and exhaustion (ICOS) (**Figure**  
429 **3a, b**) as well as increase in frequencies of senescent CD4<sup>+</sup>TIGIT<sup>+</sup> T cells. Using CD28,  
430 KLRG1, CD57, TIGIT, PD-1 and ICOS as biomarkers, higher frequencies of CD8<sup>+</sup> and  
431 CD4<sup>+</sup> T cells with mixed senescence/ exhaustion phenotypes were also observed  
432 individuals with severe COVID-19 when compared to individuals with mild disease  
433 and, for specific phenotypes, to individuals with moderate disease (**Figure 3**). This  
434 association of T cell senescence to COVID-19 severity further confirmed our hypothesis  
435 and prompt us to examine other parameters of aging as risk factors for the worse disease  
436 outcomes.

437 To further understand the influence of B cell senescence in SARS-CoV-2  
438 infection, we explored the immunoglobulin repertoire of COVID-19 patients and  
439 healthy individuals. Aging is associated with decreased lymphoid differentiation and  
440 with a consequent reduction in the output of naïve B cells. Clonal expansion of  
441 memory-like B cells in the periphery due to homeostatic proliferation and chronic  
442 stimulation by antigens result in maturation and shrinkage of the immunoglobulin  
443 repertoire <sup>7,8</sup>. Herein, we analyzed the most expanded clones to have a better grasp of

444 their representation in the overall repertoire. As shown in **Figure 4a**, the most expanded  
445 clones were not as dominating in individuals who tested negative for the disease when  
446 compared to the one who had a mild outcome. Also, we observed that individuals who  
447 were hospitalized had the most expanded clones representing a larger amount of the  
448 repertoire. In addition, hospitalized patients had lower repertoire diversity when  
449 compared to both negative and mild COVID-19 individuals (**Figure 4b**). These results  
450 correlated with previous reports demonstrating that the more severe the COVID-19 the  
451 lower the diversity of the antibody repertoire<sup>57,58</sup>. In addition, the immunoglobulin  
452 repertoire of individuals who needed to be hospitalized had a more mature profile  
453 (**Figure 4c**) characterized by altered immunoglobulin gene usage and an increased  
454 frequency of mutated antibodies structurally diverging from their germline precursors.  
455 Mature repertoires are indicators of immunosenescence because mutations accumulated  
456 with age as the frequency of germline-encoded antibodies decrease<sup>8</sup>.

457 To further explore the idea that individuals who developed severe COVID-19  
458 might have an immunosenescent phenotype, we sought to investigate the biological age  
459 of individuals within our cohort measuring DNA methylation in CpG dinucleotides.  
460 Many studies have used DNA methylation as an epigenetic clock to measure biological  
461 age since DNA methylation accumulates with aging<sup>38</sup>. The epigenetic age can be  
462 accelerated by certain diseases including HIV infection, Alzheimer's, obesity, and by  
463 chronic exposure to infectious agents even when the individuals are not infected<sup>42,16</sup>.

464 To increase the accuracy in measuring biological age by an epigenetic approach,  
465 we analyzed the DNA methylation data using 8 different clocks: the classic and updated  
466 Horvath clocks<sup>59</sup>, Hannum's, Levine's, the BLUP, Wu, EN and TL clocks, the latter  
467 focused on CpGs associated with telomere formation, expression, and  
468 maintenance<sup>27,43,46</sup>. Our results show an acceleration of epigenetic age in hospitalized  
469 patients with severe COVID-19 in 7 of the 8 analyzed clocks if we exclude individuals  
470 from Governador Valadares. Including this population, we found a similar profile result  
471 (**Figure 4d**) with a variation in one of the clocks. However, there is an increase in  
472 statistical significance in the analysis when individuals from the endemic area were  
473 included (**Figure 4e**). Thus, these data confirmed, by another approach, the tight  
474 association between the immunosenescence phenotype and COVID-19 severity.  
475 Moreover, a network analysis of integrated data on the immunosenescence profile  
476 showed that individuals who developed severe COVID-19 had clusters with higher

477 degree of integration mostly among senescent and exhausted of T cells (**Figure 4 f**). A  
478 graphical representation of all data illustrates that individuals with severe disease  
479 resemble the aged phenotype (**Figure 4 g**).

480         There were limitations in this study. Although we included only individuals with  
481 initial infection (1-4 days of symptoms), we cannot exclude the overlap between the  
482 inflammatory mediators coming from a previous state of inflammaging from the early  
483 innate response to SARS-CoV-2. This was less relevant for the analysis of senescent  
484 and exhausted T cells because we have shown that COVID-19 can induce senescence  
485 and exhaustion in CD8<sup>+</sup> and CD4<sup>+</sup> T cells after 7 days of symptoms<sup>27</sup>. It is probably the  
486 case of the repertoire analysis of antibodies that are very unlikely to have expanded due  
487 to virus stimulation in such short time of infection. However, the choice of working  
488 with individuals within 1-4 days of symptoms and the need to match all the individuals  
489 by sex, age and presence of comorbidities reduced our study sample, which was another  
490 limitation.

491         Despite these restrictions, our data clearly show a close association between a  
492 profile of immunosenescence, examined by different approaches and consolidated by  
493 network analysis, and the progression of early phase infected individuals to severe  
494 COVID-19. We also reached important non-anticipated conclusions such as the  
495 uniqueness of the inflammatory pattern associated with early COVID-19 when  
496 compared to other respiratory infections and the differences in the inflammaging and  
497 immunosenescence phenotype in endemic regions for infectious disease when compared  
498 other metropolitan areas. These results are relevant not only to uncover the pathogenesis  
499 of severe COVID-19, but they have also predictive value for future epidemic viral  
500 infections. Most of all, the data shed light on the aging process and on the consequences  
501 of accelerated senescence that affect certain endemic regions of the planet.

502

503 **Author contribution:**

504 A.M.C. designed the study, coordinate the recruitment and analysis, and wrote the  
505 manuscript; L.H.A.V. and L.T. performed sample collection and processing, Luminex  
506 and flow cytometry analysis, and wrote the manuscript; G.C.C. performed the  
507 recruitment, blood collection and sample processing of the volunteers in Belo  
508 Horizonte, discussed the results and wrote the manuscript; J.Z. performed flow



509 cytometry analysis of samples from São Paulo and discussed the results, M.M.C.  
510 performed DNA methylation analysis and discussed the results; C.H.R-P. was in the  
511 charge of sample processing and helped with the flow cytometry analysis, J.G.  
512 performed the B cell repertoire analysis and discussion under the supervision of L.F.F.,  
513 F.C.M. performed the bioinformatic analysis and discussed the results; L.N. developed  
514 the database for the study, M.A.O., V.D.M. and M.F.O. helped in sample processing,  
515 Luminex analysis and discussion of the results, L.W.Z. helped with B cell repertoire and  
516 DNA methylation analysis and the discussion of the results; M.S.C. performed the  
517 clinical exams of volunteers at UPA-Centro Sul in Belo Horizonte under the supervision  
518 of U.T.; H.I.S. performed the RT-PCR tests of all volunteers under the supervision of  
519 S.M.R.T.; H.C.G. and R.C.B. were in charge of clinical exams of volunteers recruited at  
520 Hospital Universitário Risoleta Tolentino Neves in Belo Horizonte; A.P.V., N.A.,  
521 G.P.C. and S.R. were in charge of clinical exams of volunteers recruited at Instituto de  
522 Infectologia Emílio Ribas, M.L.O.J. was in the charge of the clinical exams of  
523 volunteers recruited at Hospital Unimed in Governador Valadares; A.P.C.B. helped in  
524 the recruitment and sample processing of volunteers in Governador Valadares; F.F.C.  
525 helped in recruitment, sample collection and processing in Belo Horizonte; E.S.F.  
526 helped with the Luminex testing and data analysis supervised by O.A.M.F.; V.C. helped  
527 in the bioinformatic and statistical analysis as well as the discussion of the results, R.A.  
528 was in the charge of radiographic classification and follow-up of hospitalized patients in  
529 São Paulo; R.S. helped in the recruitment of healthy volunteers in São Paulo; G.S-N.  
530 coordinate all the recruitment and sample collection/processing of volunteers from  
531 Governador Valadares and helped in the statistical analysis; M.A. and C.L. helped in  
532 sample processing and the flow cytometry analysis of volunteers from São Paulo,  
533 T.U.M. coordinate the recruitment, questionnaire application and telemonitoring of  
534 volunteers of Belo Horizonte and helped discussing the data; D.M.F. coordinate sample  
535 processing and flow cytometry analysis in São Paulo, helped designing the experiments  
536 and discussing the data; A.T-C. supervised the flow cytometry analysis, Luminex  
537 analysis, serology tests in Belo Horizonte, helped designing the experiments and  
538 discussing the data.

539

540 **Acknowledgments:**

541 This study was supported by grants from Merck Dohme & Sharp (MISP#60383),  
542 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil,  
543 407363/2021-1), Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior  
544 (# 0688/2020, CAPES, Brazil) and Pro-reitoria de Pesquisa da Universidade Federal de  
545 Minas Gerais (PRPq-UFMG). A.M.C.F., A.T-C., D.M.F., T.U.C., O.A.M.F., G.C.C.,  
546 M.M.C., M.A.O., M.F.O., V.D.M. are recipients of research fellowships and  
547 scholarships from CNPq, L.H.A.V., L.T., L.N. are recipients of scholarships and  
548 fellowships from CAPES, Brazil, F.C.M. is recipient of a scholarship from Fundação de  
549 Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil), M.A. and C.L. are  
550 recipients of a scholarships from Fundação de Amparo à Pesquisa do Estado de São  
551 Paulo (FAPESP, Brazil).

552

### 553 **Conflict of Interest Statement**

554 The authors do not have any conflicts of interest regarding this manuscript, its  
555 preparation, or the research that went into it.

556

### 557 **Data availability statement**

558 The MiAIRR data that support the findings of this study are available in Zenodo with  
559 the identifier(s) doi:10.5281/zenodo.12789370. FASTQ files can be accessed via NCBI  
560 under the BioProject accession PRJNA1138747 or SRA SRP528303, in the project  
561 Immunosenescence of antibody repertoire in individuals from endemic areas for  
562 infectious diseases or via the link:

563 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1138747>.

564 Data are also available upon request to the corresponding author.

565

### 566 **Materials and Methods**

#### 567 ***Ethics Statement***

568 The present study was approved by the national research ethics committee in  
569 Brazil (CONEP) and by the research ethics committees of the Universidade Federal de  
570 Minas Gerais (UFMG), and of the Instituto de Infectologia Emílio Ribas (IIER) (CAAE  
571 40208320.3.2001.0061). All participants signed the informed consent form during the  
572 first evaluation, agreeing to participate in the study.

573

#### 574 *Study Population and Data Collection*

575 A total study sample of 806 volunteers were recruited in 3 cities, Belo  
576 Horizonte/MG (467 individuals), Governador Valadares/MG (176 individuals) and São  
577 Paulo/SP (163 individuals) from December 2020 to October 2021 (**Table 1 and 2**). The  
578 strains that circulated during the period were the original and P1 (Brazilian variant).  
579 Individuals with symptoms of a flu-like syndrome of unknown etiology and healthy  
580 individuals were used as study controls. Volunteer recruitment in Belo Horizonte (MG)  
581 was carried out at the Health Care Unit in the Center-South region (UPA-CS), at  
582 Hospital Risoleta Tolentino Neves, at Casa do Ancião in Cidade Ozanam and at home.  
583 In São Paulo (SP), volunteer recruitment and sample collection took place at the  
584 Instituto de Infectologia Emílio Ribas (IIER) and in Governador Valadares (MG), at  
585 Hospital da Unimed de Governador Valadares and at home for some exceptional cases.  
586 A study flowchart with an outline of recruitment and sample collection at the health  
587 units is shown in **Supplementary Figure 4**. All individuals had their blood collected  
588 and were tested using nasopharyngeal swabs samples for reverse-transcriptase  
589 quantitative polymerase-chain-reaction (RT-qPCR) detection of SARS-CoV-2. They  
590 were telemonitored for 14 days to obtain information on their clinical status.  
591 Hospitalized individuals had their clinical evolution information collected directly from  
592 their medical records. All volunteers had their weight and height measured to determine  
593 their nutritional status by using the Body Mass Index (BMI) ratio. Weight was assessed  
594 using a Balmark® device with a capacity of 200 kg and an accuracy of 100 g, while  
595 height was measured with a portable stadiometer that accommodates up to 2 meters  
596 with an accuracy of 1.0 mm. The Body Mass Index (BMI) was calculated using the  
597 formula:  $BMI = \text{weight (kg)} / \text{height}^2 \text{ (m)}$  and was subsequently classified according to  
598 their age range, based on the World Health Organization scale<sup>60</sup>. A clinical and  
599 sociodemographic questionnaire was also administered during recruitment to gather  
600 additional information, such as current symptoms, days since symptom onset,  
601 vaccination status, and medical history.

602

#### 603 *Study inclusion and exclusion criteria*

604 Initially, the inclusion criteria for the study groups were all individuals over 20  
605 years of age who had flu-like symptoms at the time of data collection. For negative  
606 individuals, the inclusion criterion at recruitment was all individuals who were never  
607 diagnosed with COVID-19 nor had flu-like symptoms with a confirmed negative RT-  
608 PCR test for SARS-CoV-2 infection and who tested negative for serological  
609 quantification of the following 4 viral proteins: spike 1, spike 2, nucleocapsid and  
610 receptor binding domain (RBD).

611 Exclusion criteria were applied to any patient who took any dose of the COVID-  
612 19 vaccine, patients living with HIV, those with inconclusive RT-PCR test, missing  
613 important information in their medical records or in the health questionnaire, those with  
614 greater than 4 days of symptom onset and those with a positive anti-SARS-CoV-2 IgG  
615 or IgM serology. We included only individuals who had 1 to 4 days of symptoms to  
616 better assess possible predictors of the disease. As shown previously by our group,  
617 individuals with mild and severe COVID-19 presented an increase in the frequency of  
618 exhausted/senescent T cells and in the levels of inflammatory mediators after 7 days of  
619 symptoms with a clear difference between the ones with only 4 days of symptom  
620 onset<sup>27</sup>.

621

### 622 *Clinical Groups and Criteria for Classification of COVID-19 Patients*

623 We classified those infected with COVID-19 (positive RT-PCR for SARS-CoV-  
624 2) into different clinical forms of COVID-19 (mild, moderate and severe) according to  
625 WHO criteria (**Supplementary Table 1**). To perform certain analysis, we chose to  
626 group individuals with a moderate or severe clinical form of COVID-19 in a single  
627 group called Hospitalized since these individuals needed inpatient care. Individuals with  
628 flu-like symptoms who presented a negative RT-PCR and serological test for SARS-  
629 CoV-2 were grouped in the flu-like syndrome (FLS) group. A group of negative  
630 individuals was used in some analysis, and it consists of individuals with a negative  
631 SARS-CoV-2 test and no report of flu-like symptoms.

632

### 633 *RT-PCR for SARS-CoV-2 detection and viral load calculation*

634 RNA extraction from nasopharyngeal swab samples was performed using the  
635 QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the manufacturer's  
636 protocol. From 1 mL of Viral Transport Medium containing the collected sample, 47  $\mu$ L  
637 of each individual sample was pooled in 1.5 mL microtubes, and 150  $\mu$ L of the pool  
638 was used for extraction; the remainder was stored at  $-80^{\circ}\text{C}$  for possible repetitions. In  
639 cases where the clustering resulted in detectable results, it was necessary to individually  
640 process all samples present in the respective cluster. RT-qPCR was performed using the  
641 QuantStudio™ 3 and 5 real-time PCR systems (Applied Biosystems™, United States).  
642 For viral RNA detection, the recommendations described by the Charité protocol <sup>61</sup>  
643 were followed, which targets the gene (E) encoding the viral envelope protein, with a  
644 reported sensitivity of 3.9 copies of the SARS-CoV-2 genome per reaction <sup>61</sup>. Thermal  
645 cycling was performed at  $55^{\circ}\text{C}$  for 10 min for reverse transcription, followed by  $95^{\circ}\text{C}$   
646 for 3 min and then 45 cycles of  $95^{\circ}\text{C}$  for 15 s,  $58^{\circ}\text{C}$  for 30 s. For endogenous control of  
647 the reaction, the gene encoding human RNaseP was used as a target.

648

#### 649 ***Blood collection and isolation of PBMC***

650 Peripheral blood mononuclear cells (PBMC) were obtained by blood collection  
651 from COVID-19 and control patients using heparinized vacuette. The purification was  
652 attained by Ficoll gradient (Histopaque – 1077; Sigma) centrifugation at room  
653 temperature, in a 1:2 ratio, for 40 minutes, at 1400 revolutions per minute (RPM)  
654 without breaking. After that, PBMCs were collected using a Pasteur pipette, washed  
655 with RPMI medium at 500x for 7 minutes at  $4^{\circ}\text{C}$ , and then red cells were lysed using a  
656 lysis buffer. A second wash using RPMI was conducted. Cells were counted and stored  
657 in fetal bovine serum supplemented with 10% dimethyl sulfoxide at  $-80^{\circ}\text{C}$  until use.  
658 Samples were processed up to 48 hours after collection.

659

#### 660 ***Plasma and Serum Isolation***

661 Blood was collected into heparin tubes for plasma obtention, and in serum  
662 separator tubes containing clot activator. Plasma and serum samples were isolated after  
663 whole blood centrifugation at 3000 RPMs for 10 minutes at  $20^{\circ}\text{C}$ , then carefully split  
664 into 2mL aliquots and stored at  $-80^{\circ}\text{C}$  until the time of testing, Samples were processed  
665 up to 48 hours after collection.

666

667 ***Measurement of cytokines, chemokines, and growth factors by Luminex-Multiplex***

668 The measurement of biomarkers was performed in heparinized plasma for  
669 detection and quantification of analytes for all 309 individuals from Belo Horizonte,  
670 São Paulo and Governador Valadares (endemic area) all in Brazil. The Bio-Rad  
671 Laboratories kit (Bio-Plex® Pro Human Cytokine Standard) was used, allowing for the  
672 analysis of several analytes to be analyzed simultaneously, using the magnetic  
673 immunoassay technique carried out with the Luminex equipment (Bio-Plex® 200, Bio-  
674 Rad), following storage and processing protocols standardized by the Grupo Integrado  
675 de Pesquisa com Biomarcadores (GIPB) (IRR-FIOCRUZ/MG). Samples were  
676 transported and stored at a temperature of -80°C. Analyses were performed using  
677 Bioplex™ xPONENT version 3.1 software (Bio-Rad), and presented the following  
678 panel of analytes: IL-1 $\beta$ , IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8, IL-9, IL-10, IL-  
679 12p70, IL-13, IL-15, IL-17A, CCL11, Basic-FGF, G-CSF, GM-CSF, IFN- $\gamma$ , CXCL10,  
680 CCL2, CCL3, CCL4, PDGF-BB, CCL5, TNF and VEGF.

681 In all the inflammatory analysis carried out in the present study, we identified 10  
682 of the 27 mediators evaluated as those that are most present in the analyses, configuring  
683 a possible signature of these mediators in our population (CCL2, CXCL8, CXCL10, IL-  
684 6, IL12(p70), IFN- $\gamma$ , IL-1Ra, IL-10, TNF, IL-6) and in order not to dilute the data, we  
685 chose to show the differences only within this signature.

686

687 ***Measurement of chemokines by Cytometric Bead Array (CBA)***

688 The CBA assay was performed using the BD Cytometric Bead Array (CBA) –  
689 Human Chemokine Kit to complete the Luminex Bio-plex assay biomarker panel. The  
690 chemokines present in the kit are CCL2, CCL5, CXCL8, CXCL9 and CXCL10.  
691 Samples from Belo Horizonte-MG, Governador Valadares-MG and São Paulo-SP, all  
692 previously prepared before the test, were included. Kit reagents were previously filtered,  
693 and kit protocol was standardized and used. Samples were purchased from BD  
694 FACSVerse.

695

696 ***Measurement of SARS-CoV-2 viral proteins by Luminex-Multiplex***

697 The measurement of biomarkers was performed in serum for detection and  
698 quantification of proteins for 144 negatives individuals from Belo Horizonte, São Paulo  
699 and Governador Valadares (endemic area) all in Brazil. The Bio-Plex Multiplex SARS-  
700 CoV-2 Serology Assay Kit was used, allowing the analysis of the following viral  
701 proteins: Spike 1, Spike 2, Nucleocapsid and receptor binding domain (RBD). All  
702 samples were analyzed simultaneously using the magnetic immunoassay technique  
703 performed with the Luminex equipment (Bio-Plex® 200; Bio-Rad) and according to the  
704 storage and processing protocols standardized by the Grupo Integrado de Pesquisa com  
705 Biomarcadores (GIPB) (IRR - FIOCRUZ/MG). Samples were transported and stored at  
706 -80°C. Analysis were performed using Bioplex™ xPONENT software version 3.1 (Bio-  
707 Rad).

708

#### 709 *Measurement of Vitamin D*

710 The biochemical test to measure vitamin D levels was outsourced to a clinical  
711 analysis laboratory in Belo Horizonte, which has all the laboratory quality certifications  
712 in order. The serum levels of this vitamin were measured by chemiluminescence using  
713 the Atellica Siemens device. All tests were performed respecting the transport and  
714 storage conditions established by the outsourced company.

715

#### 716 *Immunophenotype by polychromatic flow cytometry*

717 PBMCs ( $1 \times 10^6$ ) were first stained with LIVE/DEAD fixable aqua dead cell stain  
718 (ThermoFisher Scientific, cat #L34957) and with fluorophore-conjugated monoclonal  
719 antibodies to human surface markers. All information on the antibodies, their  
720 concentrations, manufacturer and catalogue numbers can be found in **Supplementary**  
721 **Table 2**. After the surface staining, cells were fixed and permeabilized using the  
722 Foxp3/Transcription Factor Staining Buffer Set from eBioscience (cat #00-5523-00)  
723 and stained for -Foxp3 from ImmunoTools (3G3, cat# 21276106) (Supplementary  
724 Table 2). Single-color labelled cells for fluorescence compensation were prepared with  
725 antibody capture compensation beads (BD Biosciences). Cell samples were acquired in  
726 a BD LSRFortessa cell analyzer (BD Biosciences) coupled to computers with DIVA  
727 and FlowJo-10 *software* (Tree Star). One hundred events for each sample were acquired

728 in the lymphocyte gate. The gate strategy used to analyze T lymphocyte populations is  
729 shown in **Supplementary Figure 3**.

730

### 731 *Extraction of DNA and RNA from PBMC and Bisulphite Treatment*

732 Frozen samples of PBMCs were briefly thawed in a 37°C water bath and kept on  
733 ice. Pellets were then resuspended in 1ml Trizol and incubated at room temperature.  
734 Chloroform was then added to each sample. After homogenization and further  
735 incubation, samples were centrifuged to form a three-phase solution. The aqueous phase  
736 was used for RNA extraction and the interphase was used for DNA extraction. Thus,  
737 both samples underwent purification and quantification steps and, after elution, were  
738 stored in a -80°C freezer in low-binding plastic microtubes. Genomic DNA extraction  
739 was performed using the QIAamp 96 DNA Blood kit (QIAGEN, Hilden, Germany).  
740 DNA (1 µg) was bisulphite-converted using the EZ-96 DNA Methylation Kit (Zymo  
741 Research, Irvine, USA) with the following modifications: incubation in CT buffer for  
742 21 cycles of 15 min at 55 °C and 30 s at 95 °C, elution of bisulphite-treated DNA in 100  
743 µl of water. After extraction and conversion, samples were loaded on the Illumina  
744 Infinium MethylationEPIC BeadChip.

745

### 746 *Analyses of Epigenetic Aging: Obtaining Raw Methylation Data*

747 DNA from the PBMC samples was extracted according to the Trizol and  
748 chloroform protocol. Subsequently, DNA was hybridized using the Illumina Infinium  
749 MethylationEPIC Beadchip (EPIC array) that covers nearly 850,000 CpG sites in the  
750 human genome. The watermelon 2.4.0 R package (Pidsley et al., 2013) was used to  
751 perform raw data processing, batch effect correction, and obtain matrices with  
752 methylation  $\beta$  value. The methylation  $\beta$  value for each CpG site in each sample was  
753 calculated to represent the level of methylation.

754

### 755 *DNA methylation age calculation*

756 We used the mDNA age of epigenetic clocks created based on blood samples,  
757 including the Horvath clock with 353 CpGs based on various tissue types, the



758 skinHorvath clock that integrated the whole blood dataset with skin, endothelial cells,  
759 buccal mucosa and saliva, the Levine clock based on 513 CpGs derived from whole  
760 blood, the TL telomere length clock based on 140 CpGs derived from blood, the BLUP  
761 clock based on 319607 CpGs derived from blood, the EN clock based on 514 CpGs  
762 derived from all blood and the Hannum watch with 71 CpGs identified in blood DNA  
763 samples. The deviation between epigenetic age and chronological age, also known as  
764 epigenetic age acceleration, was calculated for each sample based on mDNA age  
765 regression residuals considering cell counts with the R methylclock 1.5.0 package<sup>62</sup>.

766

767 ***B cells repertoire analysis using immunoglobulin variable heavy chain (IGVH)***  
768 ***amplification***

769 A subset of 45 individuals was analyzed to examine their B cell repertoire. For this,  
770 RNA was extracted from frozen PBMC samples of these individuals using Trizol  
771 (ThermoFisher). The cDNA was synthesized with SuperScript IV First-Strand Synthesis  
772 System (ThermoFisher) from approximately 500 ng of RNA, following the  
773 manufacturer's instructions. IGVH amplification was performed using 0.2 mM of  
774 forward primers (1 to 8; **Supplementary Table 4**), 0.1 mM of each IgG and IgA  
775 reverse primers (9 and 10; Supplementary Table 4), 0.2 units (U) of Platinum™ Taq  
776 DNA Polymerase High Fidelity (Invitrogen), 1X High Fidelity PCR Buffer solution, 0.2  
777 mM of dNTPs, 1 mM of MgSO<sub>4</sub>, and 2 μL of cDNA in a final volume of 50 μL. The  
778 PCR reaction was conducted using the following program: 2 minutes (min) at 95 °C; 4  
779 cycles of 94°C for 30 seconds (sec), 50°C for 30 sec, and 68°C for 1 min; 4 cycles of  
780 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min; 22 cycles of 94°C for 30 sec,  
781 63°C for 30 sec; 68°C for 7 min and final hold at 4°C. Samples GV47, GV50, GV51,  
782 GV54, GV92, GV106, GV144, and GV146 were amplified using the NEBNext® High-  
783 Fidelity 2X PCR Master Mix (New England Biosciences, UK). Forward primers at a  
784 final concentration of 0.2 mM, IgG/IgA reverse primers at 0.1 mM, and 2 μL of cDNA  
785 were added to 1x PCR Master Mix in a final volume of 50 μL. The cycling conditions  
786 were the same as described above, except for an extension temperature of 72° C. Four  
787 replicates were amplified for each sample. The mixed 200 μL of PCR product of each  
788 sample was precipitated using Puregene® Concentrating DNA protocol (Qiagen,  
789 Germany). IgG/IgA amplification was excised from an electrophoresis run of 1%  
790 agarose gel, followed by the PCR purification protocol provided by NucleoSpin Gel and

791 PCR Clean-up kit (Macherey-Nagel). The concentration of the DNA was calculated  
792 using Nanodrop and Qubit DNA High Sensitivity kit (ThermoFisher Scientific).

793

#### 794 ***Library construction and sequencing***

795 Sequencing libraries were constructed using the Nextera XT DNA Library Prep Kit  
796 (Illumina) according to the manufacturer's instructions. A PCR reaction was prepared to  
797 contain: 5 µl of Nextera CD Index 1 (i7) Primer (H7XX); 5 µl of Nextera CD Index 2  
798 (i5) Primer (H5XX); 1X of the High-Fidelity PCR Buffer solution; 0,2 mM of dNTPs; 1  
799 mM of MgSO<sub>4</sub>; 1 U of Platinum® Taq DNA High Fidelity Polymerase; 5 µl (if DNA  
800 concentration >= 10 ng/µl) or 10 µl (if DNA concentration ranged from 5 -10 ng/µl) of  
801 the gel purified amplicon in a final volume of 50 µl. The cycling condition was 3 min at  
802 95 °C; 12 cycles of 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min; 68°C for 5  
803 min; and hold at 4°C. The PCR product was purified with 0.5 volumes of Agencourt  
804 AMPure XP beads and the library was quantified using the Qubit DNA High Sensitivity  
805 kit (ThermoFisher Scientific). Amplicon size was inferred using the High Sensitivity  
806 DNA Kit (Agilent) run on the Bioanalyzer 2100 (Agilent). Sequencing was performed  
807 on the Illumina MiSeq System (Illumina), using the Miseq Reagent Kit v3 (600-Cycle)  
808 (Illumina) with 301 sequencing cycles for each forward and reverse read. A total of 31  
809 different libraries from the volunteers were joined equimolarly in a pool of 4nM and  
810 diluted to 18 picomolar for further sequencing. A summary of found sequences are in  
811 **Supplementary Table 4.**

812

#### 813 ***Bioinformatic analysis: Pre-processing***

814 Samples were demultiplexed by the Illumina sequencer tool or using an in-house script  
815 resulting in FASTQ files. All pre-processing was done using the framework  
816 Immcantation and it consists of 4 steps: 1) Using pRESTO<sup>63</sup>, the AssemblePairs  
817 module was used to join the sequence, based on the 3'-5' read and the 5'-3' read, with a  
818 minimum overlap of 50 nucleotides; 2) Quality filter was applied by using the module  
819 FilterSeq<sup>63</sup> Only sequences with a Phred score >=30 were selected; 3) The module  
820 MaskPrimers<sup>63</sup> was employed to find the primers of the IGHV gene and constant  
821 region. The option score was employed, preserving sequences with both forward and

822 reverse primers intact; any sequences not meeting these conditions were filtered out; 4)  
823 Annotation was performed with the AssignGenes module from Change-O<sup>63</sup> together  
824 with IgBlast<sup>64</sup> to verify similarities between the subject and query. IMGT human  
825 germline was used as a reference for V, J, and D genes, as well as their numbering  
826 system<sup>65</sup>; the MakeDB module was run to organize the alignment into a tabular .tsv file  
827 in the MiAIRR format<sup>66</sup>. This format contains information on V, D, and J genes and  
828 alleles, framework (fw), complementary regions sequences (cdr), and functional status  
829 of the sequence (productive or unproductive).

830

### 831 ***Bioinformatic analysis: Clonotyping and Diversity Analysis***

832 The sequences were grouped into clones using the tool YClon<sup>67</sup>. Shannon diversity was  
833 calculated using the *diversity* function of the R package ‘vegan’ ([https://CRAN.R-](https://CRAN.R-project.org/package=vegan)  
834 [project.org/package=vegan](https://CRAN.R-project.org/package=vegan)). Diversity was compared between groups of individuals  
835 with flu-like symptoms or control ( $n=6$ ), with the ones with mild COVID ( $n=19$ ), and  
836 severe COVID-19 ( $n=20$ ) from Belo Horizonte, São Paulo and Governador Valadares  
837 (only mild cases). Diversity was computed for the 100 most expanded clones from each  
838 repertoire. The complete pipeline employed to prepare and analyze the IGH repertoire is  
839 available on <https://github.com/jao321/covidao.git>.

840

### 841 ***Repertoire Maturity Analysis***

842 We define repertoire maturity as the extent to which an individual's immune repertoire  
843 has diverged from germline-like sequences through processes such as somatic  
844 hypermutation and clonal selection. A more mature repertoire is characterized by a  
845 lower proportion of germline-like clones, reflecting immune system adaptation and  
846 experience with antigens over time. To gain a more profound insight into the maturity  
847 of the repertoire, an investigation was conducted to identify the sequence closest to the  
848 germline for each clone, encompassing both the V and J genes. To achieve this, we  
849 considered the difference in length between the V gene (5 to 6 times longer than the J  
850 gene) to ensure a comprehensive analysis, using the following calculation:

851  $VJpid = (Vpid * 0.8) + (Jpid * 0.2)$

852 VJpid: Percentage of the expected identity of the V and J genes when compared to  
853 the germline

854 VJpid: Percentage of identity of V genes compared to germline

855 VJpid: Percentage of the identity of the J gene when compared to the germline

856 Only the sequence with the highest VJpid value for each clone remained, as these  
857 sequences have undergone fewer mutations.

858

### 859 *Statistical Analysis*

860 The Shapiro-Wilk and Kolmogorov-Smirnov tests were applied to determine whether  
861 the data had a normal (parametric) or non-normal (non-parametric) distribution. Outliers  
862 were excluded using the ROUT test. For each group, Mann-Whitney test or Kruskal-  
863 Wallis with Dunn's post-test was performed depending on the data distribution normal  
864 or non-normal. The violin plot was chosen to demonstrate the statistical significance of  
865 our analyses. Its format is directly proportional to the dispersion of the data, the dotted  
866 lines correspond to the minimum quartiles in the lower part and maximum in the upper  
867 part, and the solid line represents the median. Data are represented by black dots (each  
868 dot represents an individual) and were normalized in log<sub>10</sub>. In addition, all groups  
869 received a specific color that represents them in all graphs and figures.

870

### 871 *Radar-Chart*

872 The radar chart is a graph that represents the frequency (in percentage) of high  
873 producers of each plasma mediator represented and it has been previously described <sup>17</sup>.  
874 On the charts, each axis represents the percentage (%) of volunteers showing high levels  
875 of a specific mediator. The values of each axis can be connected to form a central  
876 polygonal area that represents 50% of the baseline level and the external polygonal area  
877 is equivalent to 100%. Increase or decrease of the central polygonal area reflects either  
878 a higher or a lower contribution of the mediators for each group. We consider all  
879 mediators that are above the internal polygonal area to be high producers.

880

### 881 *Network analysis*

882 A weighted network analysis was used to investigate the correlations between  
883 biologically relevant markers associated with cytokines and cellular proteins (listed in

884 **Supplementary Table 5** and selected based on their potential relevance for the study).  
885 To quantify the relationships between these markers, we utilized Spearman Rank  
886 correlation, a non-parametric method that ranks the data points for each variable and  
887 calculates the correlation coefficient based on the ranks. This approach is suitable for  
888 data that may not follow a normal distribution or have outliers. The correlation  
889 coefficient ranges from -1 to 1, where 1 indicates a perfect positive correlation, -1  
890 indicates a perfect negative correlation, and 0 indicates no correlation. To focus on  
891 significant correlations, we established a threshold of p-values less than 0.05. This  
892 filtering step ensured that only statistically significant relationships were included in the  
893 network analysis. The resulting network was visualized using a spring layout, a graph  
894 drawing algorithm that positions nodes based on the forces of attraction and repulsion  
895 between them. This layout is particularly effective for identifying clusters or modules  
896 within the network, providing insights into the underlying structure of the relationships.  
897 The strength of correlations was visually represented by the darker of the lines  
898 connecting nodes. Darker lines indicated stronger relationships between variables, while  
899 lighter lines suggested weaker associations. Additionally, the size of each node  
900 corresponded to the number of correlations it participated in, providing a visual cue for  
901 the variable's centrality within the network. Larger nodes represented variables with  
902 more connections, highlighting their importance in the overall system. By visualizing  
903 the network in this manner, we were able to gain insights into the interactions between  
904 cytokines/chemokines and cellular proteins, identifying key players and potential  
905 regulatory mechanisms within the biological system under study.

906

## 907 **References**

- 908 1. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the  
909 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a  
910 Report of 72314 Cases from the Chinese Center for Disease Control and  
911 Prevention. *JAMA - J. Am. Med. Assoc.* **323**, 1239–1242 (2020).
- 912 2. Grasselli, G. *et al.* Baseline Characteristics and Outcomes of 1591 Patients  
913 Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.  
914 *JAMA* **323**, 1574–1581 (2020).
- 915 3. Cerqueira-Silva, T. *et al.* Influence of age on the effectiveness and duration of

- 916 protection of Vaxzevria and CoronaVac vaccines: A population-based study.  
917 *Lancet Reg. Heal. - Am.* **6**, 100154 (2022).
- 918 4. Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of  
919 the Immune Response With Aging: Immunosenescence and Its Potential Impact  
920 on COVID-19 Immune Response. *Front. Immunol.* **11**, (2020).
- 921 5. Faria, A. M. C. & Franceschi, C. Population Immunology: Germs, Aging and  
922 Inflammation. in *Eco-immunology* (2014)145-161 (Springer Netherlands, 2014).  
923 doi:10.1007/978-94-017-8712-3\_8
- 924 6. Santoro, A., Bientinesi, E. & Monti, D. Immunosenescence and inflammaging in  
925 the aging process: age-related diseases or longevity? *Ageing Res. Rev.* **71**,  
926 101422 (2021).
- 927 7. Martin, V., Wu, Y.-C. (Bryan), Kipling, D. & Dunn-Walters, D. Ageing of the B-  
928 cell repertoire. *Philos. Trans. R. Soc. B Biol. Sci.* **370**, 20140237 (2015).
- 929 8. Ghraichy, M. *et al.* Maturation of the Human Immunoglobulin Heavy Chain  
930 Repertoire With Age. *Front. Immunol.* **11**, (2020).
- 931 9. Ciabattini, A. *et al.* Vaccination in the elderly: The challenge of immune changes  
932 with aging. *Semin. Immunol.* **40**, 83–94 (2018).
- 933 10. Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its  
934 Potential Contribution to Age-Associated Diseases. *Journals Gerontol. Ser. A*  
935 *Biol. Sci. Med. Sci.* **69**, S4–S9 (2014).
- 936 11. Talbot, H. K. Influenza in Older Adults. *Infect. Dis. Clin. North Am.* **31**, 757–766  
937 (2017).
- 938 12. Kimball, A. *et al.* Asymptomatic and Presymptomatic SARS-CoV-2 Infections in  
939 Residents of a Long-Term Care Skilled Nursing Facility — King County,  
940 Washington, March 2020. *MMWR. Morb. Mortal. Wkly. Rep.* **69**, 377–381  
941 (2020).
- 942 13. Caruso, C. *et al.* Lessons from Sicilian centenarians for anti-ageing medicine.  
943 The Oxi-inflammatory status. *Transl. Med. @ UniSa* **24**, 16–23 (2022).
- 944 14. Torres, K. C. L. *et al.* Immune senescence and biomarkers profile of Bambuí

- 945 aged population-based cohort. *Exp. Gerontol.* **103**, 47–56 (2018).
- 946 15. Lima-Silva, M. L. *et al.* A nationwide study on immunosenescence biomarkers  
947 profile in older adults: ELSI-Brazil. *Exp. Gerontol.* **191**, 112433 (2024).
- 948 16. Durso, D. F. *et al.* Living in endemic area for infectious diseases accelerates  
949 epigenetic age. *Mech. Ageing Dev.* **207**, 111713 (2022).
- 950 17. Silveira-Nunes, G. *et al.* Lifewide profile of cytokine production by innate and  
951 adaptive immune cells from Brazilian individuals. *Immun. Ageing* **14**, 2 (2017).
- 952 18. Batista, M. A. *et al.* Inflammaging in Endemic Areas for Infectious Diseases.  
953 *Frontiers in Immunology* **11**, (2020).
- 954 19. Silveira-Nunes, G. *et al.* Hypertension Is Associated With Intestinal Microbiota  
955 Dysbiosis and Inflammation in a Brazilian Population. *Front. Pharmacol.* **11**,  
956 258 (2020).
- 957 20. Comin, F., Speziali, E., Correa-Oliveira, R. & Faria, A. M. C. Aging and immune  
958 response in chronic human schistosomiasis. *Acta Trop.* **108**, 124–130 (2008).
- 959 21. Sargiacomo, C., Sotgia, F. & Lisanti, M. P. COVID-19 and chronological aging:  
960 senolytics and other anti-aging drugs for the treatment or prevention of corona  
961 virus infection? *Aging (Albany, NY)*. **12**, 6511–6517 (2020).
- 962 22. Aviv, A. Telomeres and COVID-19. *FASEB J.* **34**, 7247–7252 (2020).
- 963 23. Omarjee, L. *et al.* Targeting T-cell senescence and cytokine storm with  
964 rapamycin to prevent severe progression in COVID-19. *Clin. Immunol.* **216**,  
965 108464 (2020).
- 966 24. Bonafè, M. *et al.* Inflamm-aging: Why older men are the most susceptible to  
967 SARS-CoV-2 complicated outcomes. *Cytokine Growth Factor Rev.* **53**, 33–37  
968 (2020).
- 969 25. Cao, X. *et al.* Accelerated biological aging in COVID-19 patients. *Nat. Commun.*  
970 **13**, 2135 (2022).
- 971 26. Franzen, J. *et al.* Epigenetic Clocks Are Not Accelerated in COVID-19 Patients.  
972 *Int. J. Mol. Sci.* **22**, 9306 (2021).
- 973 27. Pedroso, R. B. *et al.* RAPID PROGRESSION OF CD8 AND CD4 T CELLS TO

- 974 CELLULAR EXHAUSTION AND SENESCENCE DURING SARS-CoV2  
975 INFECTION. *J. Leukoc. Biol.* **116**, (2024).
- 976 28. Peres, K. C., Riera, R., Martimbianco, A. L. C., Ward, L. S. & Cunha, L. L. Body  
977 Mass Index and Prognosis of COVID-19 Infection. A Systematic Review. *Front.*  
978 *Endocrinol. (Lausanne)*. **11**, 5985–6004 (2020).
- 979 29. Wang, B., Li, R., Lu, Z. & Huang, Y. Does comorbidity increase the risk of  
980 patients with COVID-19: evidence from meta-analysis. *Aging (Albany, NY)*. **12**,  
981 6049–6057 (2020).
- 982 30. Hayden, F. G. *et al.* Baloxavir Marboxil for Uncomplicated Influenza in Adults  
983 and Adolescents. *N. Engl. J. Med.* **379**, 913–923 (2018).
- 984 31. Sun, J. *et al.* Pathogenicity of fowl adenovirus serotype 4 (FAdV-4) in chickens.  
985 *Infect. Genet. Evol.* **75**, 104017 (2019).
- 986 32. Juanola-Falgarona, M. *et al.* Ct values as a diagnostic tool for monitoring SARS-  
987 CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. *Int. J.*  
988 *Infect. Dis.* **122**, 930–935 (2022).
- 989 33. Mariani, J. *et al.* Association Between Vitamin D Deficiency and COVID-19  
990 Incidence, Complications, and Mortality in 46 Countries: An Ecological Study.  
991 *Heal. Secur.* **19**, 302–308 (2021).
- 992 34. Marshall, J. C. *et al.* A minimal common outcome measure set for COVID-19  
993 clinical research. *The Lancet Infectious Diseases* **20**, e192–e197 (2020).
- 994 35. Fulop, T. *et al.* Immunosenescence and Inflamm-Aging As Two Sides of the  
995 Same Coin: Friends or Foes? *Front. Immunol.* **8**, (2018).
- 996 36. Sayed, N. *et al.* Author Correction: An inflammatory aging clock (iAge) based on  
997 deep learning tracks multimorbidity, immunosenescence, frailty and  
998 cardiovascular aging. *Nat. Aging* **1**, 598–615 (2021).
- 999 37. Faria, A. M. C. *et al.* Variation Rhythms of Lymphocyte Subsets during Healthy  
1000 Aging. *Neuroimmunomodulation* **15**, 365–379 (2008).
- 1001 38. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.*  
1002 **14**, R115 (2013).



- 1003 39. Levine, M. E. *et al.* An epigenetic biomarker of aging for lifespan and  
1004 healthspan. *Aging (Albany NY)* **10**, 573–591 (2018).
- 1005 40. Hannum, G. *et al.* Genome-wide Methylation Profiles Reveal Quantitative Views  
1006 of Human Aging Rates. *Mol. Cell* **49**, 359–367 (2013).
- 1007 41. Lu, A. T. *et al.* DNA methylation-based estimator of telomere length. *Aging*  
1008 (*Albany, NY*). **11**, 5895–5923 (2019).
- 1009 42. Field, A. E. *et al.* DNA Methylation Clocks in Aging: Categories, Causes, and  
1010 Consequences. *Mol. Cell* **71**, 882–895 (2018).
- 1011 43. Tizazu, A. M., Mengist, H. M. & Demeke, G. Aging, inflammaging and  
1012 immunosenescence as risk factors of severe COVID-19. *Immun. Ageing* **19**, 53  
1013 (2022).
- 1014 44. Camell, C. D. *et al.* Senolytics reduce coronavirus-related mortality in old mice.  
1015 *Science (80-. )*. **373**, (2021).
- 1016 45. Arcanjo, A. *et al.* Critically ill COVID-19 patients exhibit hyperactive cytokine  
1017 responses associated with effector exhausted senescent T cells in acute infection.
- 1018 46. Biasi, S. De *et al.* Marked T cell activation, senescence, exhaustion and skewing  
1019 towards TH17 in patients with COVID-19 pneumonia. *Nat. Commun.* **11(1)**,  
1020 (2020).
- 1021 47. Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe  
1022 COVID-19. *Nature* **584**, 463–469 (2020).
- 1023 48. Santoro, A. *et al.* Inflammaging, hormesis and the rationale for anti-aging  
1024 strategies. *Ageing Res. Rev.* **64**, 101142 (2020).
- 1025 49. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of  
1026 mortality due to COVID-19 based on an analysis of data of 150 patients from  
1027 Wuhan, China. *Intensive Care Med.* **46**, 846–848 (2020).
- 1028 50. Fricke-Galindo, I. & Falfán-Valencia, R. Genetics Insight for COVID-19  
1029 Susceptibility and Severity: A Review. *Front. Immunol.* **12**, (2021).
- 1030 51. Callahan, V. *et al.* The Pro-Inflammatory Chemokines CXCL9, CXCL10 and  
1031 CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-

- 1032           Dependent Manner. *Viruses* **13** (6), 1062 (2021).
- 1033   52.   Alves, V. R. G. *et al.* Influenza A(H1N1)pdm09 infection and viral load analysis  
1034           in patients with different clinical presentations. *Mem. Inst. Oswaldo Cruz* **115**,  
1035           (2020).
- 1036   53.   Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after  
1037           PD-1 therapy. *Nature* **537**, 417–421 (2016).
- 1038   54.   Zhao, Y., Shao, Q. & Peng, G. Exhaustion and senescence: two crucial  
1039           dysfunctional states of T cells in the tumor microenvironment. *Cell. Mol.*  
1040           *Immunol.* **17**, 27–35 (2020).
- 1041   55.   Pieren, D. K. J. *et al.* Co-Expression of TIGIT and Helios Marks  
1042           Immunosenescent CD8+ T Cells During Aging. *Front. Immunol.* **13**, (2022).
- 1043   56.   Pereira, B. I. & Akbar, A. N. Convergence of Innate and Adaptive Immunity  
1044           during Human Aging. *Front. Immunol.* **7**, (2016).
- 1045   57.   Galson, J. D. *et al.* Deep Sequencing of B Cell Receptor Repertoires From  
1046           COVID-19 Patients Reveals Strong Convergent Immune Signatures. *Front.*  
1047           *Immunol.* **11**, (2020).
- 1048   58.   Jia, C. *et al.* Immune repertoire sequencing reveals an abnormal adaptive immune  
1049           system in COVID-19 survivors. *J. Med. Virol.* **95**(1), (2023).
- 1050   59.   Horvath, S. & Levine, A. J. HIV-1 Infection Accelerates Age According to the  
1051           Epigenetic Clock. *J. Infect. Dis.* **212**, 1563–1573 (2015).
- 1052   60.   WHO. WHO Expert Committee on Physical Status: the Use and Interpretation of  
1053           Anthropometry (1993: Geneva, Switzerland) & World Health Organization.  
1054           (1995).
- 1055   61.   Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-  
1056           time RT-PCR. *Eurosurveillance* **25**(3), (2020).
- 1057   62.   Pelegí-Sisó, D., de Prado, P., Ronkainen, J., Bustamante, M. & González, J. R.  
1058           *methylclock*: a Bioconductor package to estimate DNA methylation age.  
1059           *Bioinformatics* **37**, 1759–1760 (2021).
- 1060   63.   Gupta, N. T. *et al.* Change-O: a toolkit for analyzing large-scale B cell

- 1061 immunoglobulin repertoire sequencing data. *Bioinformatics* **31**, 3356–3358  
1062 (2015).
- 1063 64. Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin  
1064 variable domain sequence analysis tool. *Nucleic Acids Res.* **41**, W34–W40 (2013).
- 1065 65. Lefranc, M.-P. IMGT, the International ImMunoGeneTics Information System.  
1066 *Cold Spring Harb. Protoc.* **2011**, D1006–D1012 (2011).
- 1067 66. Heiden, J. A. Vander *et al.* AIRR Community Standardized Representations for  
1068 Annotated Immune Repertoires. *Front. Immunol.* **9**, (2018).
- 1069 67. Gervasio, J. H. D. B. *et al.* How close are we to storing data in DNA? *Trends*  
1070 *Biotechnol.* **42**, 156–167 (2024).
- 1071

1072 **Figure Legends:**

1073 **Figure 1: Early inflammatory profile of COVID-19 and Flu-Like syndrome patients. (a)**

1074 Radar chart with the frequency of high mediator producers among individuals infected with  
1075 COVID-19 from Belo Horizonte and São Paulo (n=36), Mild COVID-19 (n=20), Moderate  
1076 COVID-19 (n=6) and Severe COVID-19 (n=10). **(b)** Differences in plasma mediator  
1077 concentrations in individuals with different clinical forms of COVID-19. The population used  
1078 for this analysis was the same as that used in Figure 1A. Samples were previously normalized,  
1079 and outliers were excluded using the ROUT test. Mann-Whitney test was performed  
1080 individually for each group. Lines were used to represent which groups were compared and  
1081 asterisks to represent statistical significance ( $p \leq 0.05$ ,  $**p \leq 0.01$ ,  $***p \leq 0.001$  or  $****p < 0.0001$ ).  
1082 **(c)** Radar chart representing the frequency of high mediator producers among individuals  
1083 infected with COVID-19, using individuals from Belo Horizonte and São Paulo (n=74), Flu-  
1084 Like Syndrome (n=38), Mild COVID-19 (n=42). **(d)** Comparative analysis of the concentration  
1085 of each mediator among groups. Samples were previously normalized, and outliers were  
1086 excluded from the data, using the ROUT test. Mann-Whitney test was performed individually  
1087 for each group. Asterisks to represent statistical significance ( $p \leq 0.05$ ,  $**p \leq 0.01$ ,  $***p \leq 0.001$  or  
1088  $****p < 0.0001$ ). **(e)** Radar charts representing the frequency of high producers of plasma  
1089 mediators in individuals from Belo Horizonte (n=46) with Flu-Like Syndrome (n=13), Mild  
1090 COVID-19 (n=14), Hospitalized COVID-19 (n=12) and COVID-19 Progression (n=7). The  
1091 Hospitalized COVID-19 group consists of individuals who were hospitalized with either  
1092 moderate or severe COVID-19. **(f)** Analysis of the concentration of plasma mediators of  
1093 individuals from Belo Horizonte with either COVID-19 or Flu-Like Syndrome (FS). The  
1094 population used for this analysis was the same as that used in D. Asterisks represent statistical  
1095 significance ( $*p \leq 0.05$ ,  $**p \leq 0.001$ ,  $***p \leq 0.001$  or  $****p \leq 0.0001$ ). All groups presented in this  
1096 figure were matched by sex as well as age and they were composed of individuals at the initial  
1097 stage of infection (1-4 days of symptoms).

1098

1099 **Figure 2: Inflammatory profiles of adult and elderly people with Flu-like syndrome and**  
1100 **COVID-19 living in endemic and in non-endemic areas for infectious diseases. (a)**

1101 Radar chart representing the frequency of high producers of mediators among individuals from  
1102 Governador Valadares (n=56) with either Flu-Like Syndrome (n=30) or Mild COVID-19  
1103 (n=26). **(b)** Comparative analysis of concentrations of plasma mediators in individuals with  
1104 either Flu-like syndrome or Mild COVID-19. Samples were previously normalized, and outliers  
1105 were excluded using the ROUT test. Mann-Whitney test was performed individually for each  
1106 group. Asterisks represent statistical significance ( $p \leq 0.05$ ,  $**p \leq 0.01$ ,  $***p \leq 0.001$  or

1107 \*\*\*\* $p < 0.0001$ ). (c) Radar charts representing the frequency of high producers of mediators  
1108 among individuals with COVID-19 in the adult (20-59 years) and elderly (over 60 years) age  
1109 groups in a non-endemic area (Belo Horizonte and São Paulo) - Adults (n=92) with Flu-Like  
1110 Syndrome (n=45) and Mild COVID-19 (n=47) and elderly (n=19) with Flu-Like Syndrome  
1111 (n=11) or Mild COVID-19 (n=8) and in an endemic area (Governador Valadares) - Adults  
1112 (n=75) with Flu-Like Syndrome (n=39) and Mild COVID-19 (n=36) and elderly (n=11) with  
1113 Flu-Like Syndrome (n=5) and Mild COVID-19 (n=6) (d) Radar charts representing the  
1114 frequency of high producers of CXCL9 among all individuals with Flu-Like Syndrome and  
1115 COVID-19 in the adult and elderly age groups - (Adults n=40) with FS (n=14), Mild COVID-19  
1116 (n=15) and Hospitalized (n=11), elderly (n=26) with FLS (n=13), Mild COVID-19 (n=7) and  
1117 Hospitalized (n=6). (e) Comparative analysis of plasma concentrations of CXCL-9 in  
1118 individuals with different clinical forms of COVID-19. Samples were previously normalized,  
1119 and outliers were excluded using the ROUT test. Mann-Whitney test was performed  
1120 individually for each group. Asterisks represent statistical significance ( $p \leq 0.05$ , \*\* $p \leq 0.01$ ,  
1121 \*\*\* $p \leq 0.001$  or \*\*\*\* $p < 0.0001$ ). (f) Comparative analysis of plasma concentrations of CXCL-9  
1122 in individuals with different clinical forms of COVID-19. The population used is the same  
1123 shown in Figure 2C. Samples were previously normalized, and outliers were excluded from the  
1124 data using the ROUT test. Thus, the Mann-Whitney test was performed individually for each  
1125 group. Lines were used to represent which groups were compared and asterisks to represent  
1126 statistical significance ( $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$  or \*\*\*\* $p < 0.0001$ ). All groups presented  
1127 in this figure were matched by sex as well as age and they were composed of individuals at the  
1128 initial stage of infection (1-4 days of symptoms).

1129

1130 **Figure 3: The senescence and exhaustion profile was significantly increased in individuals**  
1131 **with moderate or severe COVID-19 compared to mild individuals in both CD8<sup>+</sup> and CD4<sup>+</sup>**  
1132 **T cells.** Patients were also stratified into 3 groups classified according to the severity of the  
1133 disease as mild (n=20), moderate (n=8) and severe (n=8). (a) Percentage of senescent and  
1134 exhausted CD8<sup>+</sup> T cells from individuals with mild, moderate and severe COVID. (b) The  
1135 gating strategy was used to analyze markers related to senescence and exhaustion together  
1136 within CD8<sup>+</sup> T cells. Senescence cells are TIGIT<sup>+</sup>; exhausted are PD-1<sup>+</sup> and ICOS<sup>+</sup>. (c)  
1137 Percentage of senescent/exhausted CD8<sup>+</sup> T cells from individuals with mild (20), moderate (8)  
1138 and severe (8) COVID-19. Senescent/exhausted CD8<sup>+</sup> T cells quantified by co-expression of  
1139 CD57<sup>+</sup> and PD-1<sup>+</sup>, CD28<sup>neg</sup> and PD-1<sup>+</sup>, TIGIT<sup>+</sup> and ICOS<sup>+</sup>. KLRG1<sup>+</sup> marker may be present in  
1140 senescent and exhausted. (d) Representative flow cytometry of senescent/exhausted CD8<sup>+</sup> T  
1141 cells, with the gate of interest showing a red square. (e) Percentage of senescent and exhausted  
1142 CD4<sup>+</sup> T cells from individuals with mild, moderate and severe COVID. (f) Dot plots of

1143 strategy was used to analyze markers related to senescence TIGIT<sup>+</sup>, CD57<sup>+</sup>, CD28neg and  
1144 KLRG1<sup>+</sup>, to exhaustion marker ICOS<sup>+</sup> and KLRG1<sup>+</sup> within CD4<sup>+</sup> T cells was used (red square).  
1145 \*p < 0.05, \*\*p < 0.01.

1146 **Figure 4: Analysis of immunoglobulin repertoires and of biological aging in patients with**  
1147 **different clinical forms of COVID-19. (a)** Graphical representation of clonal expansion of the  
1148 100 most expanded clones in the repertoire of five individuals. The more intense the color, the  
1149 more expanded the clone is. **(b)** Shannon entropy diversity was calculated using the diversity  
1150 function of the ‘vegan’ package with the 100 most expanded clones for hospitalized individuals  
1151 (n=20, Red), individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-  
1152 Cyan) from Belo Horizonte and Governador Valadares (only mild cases). Differences among  
1153 groups were calculated using Mann-Whitney test and ROUT test to exclude outliers. Asterisks  
1154 represent statistical significance (\*p<0.01). **(c)** Repertoire maturity (divergence from germline-  
1155 like sequences) was calculated for the whole repertoire of hospitalized individuals (n=20, Red),  
1156 individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-Cyan) from  
1157 Belo Horizonte and Governador Valadares (only mild cases). The ROUTE test was performed  
1158 to remove outliers. **(d)** Accelerated aging was measured using eight different epigenetic clocks  
1159 (Horvath; New Horvath; Levine; Hannum; BLUP; EN; Wu; TL) in unvaccinated COVID-19  
1160 negative control individuals (n = 12) (Blue-Cyan), infected with COVID-19 Mild 9 (n = 9)  
1161 (Yellow) and infected with Hospitalized COVID-19 (n = 17) (Red) without including endemic  
1162 area. The y-axis shows the acceleration of epigenetic age after adjustment for cell type fractions  
1163 (Residual Regression of Epigenetic Age Acceleration on Cell Type Fractions). The box plot  
1164 represents the median, interquartile, minimum and maximum values of age acceleration (in  
1165 years) determined for each group. One-way ANOVA and t-test were used to evaluate significant  
1166 differences. Values of p < 0.05 were considered statistically significant (\*). **(e)** The same  
1167 analysis as in Figure 4D was performed but including individuals from endemic areas. The  
1168 population used includes unvaccinated COVID-19 negative control individuals (n = 12) (Blue-  
1169 Cyan), infected with COVID-19 Mild 9 (n = 18) (Yellow) and infected with COVID-19  
1170 Hospitalized (n = 18) (Red). **(f)** Biological network of cytokines and cellular proteins of  
1171 exhaustion and senescence in infected individuals with mild and severe COVID-19. Patients  
1172 who developed severe COVID-19 showed greater interactions with biomarkers of senescence  
1173 and exhaustion in immune cells (including cytokines, chemokines, and cell surface markers) up  
1174 to 4 days after infection, when compared to patients who developed the mild form of the  
1175 disease. Blue thicker lines indicate positive correlations and red thicker lines negative  
1176 correlations. The description of the codes present in the graph is in Supplementary Table 5. The  
1177 size of the circles is proportional to their importance as hubs of connection. **(g)** A graphical  
1178 representation of the main biomarkers of aging (cytokines/chemokines, Ig repertoire, DNA

1179 methylation, cellular markers of exhaustion and senescence) illustrates the comparative  
1180 differences between individuals with Mild and Severe COVID-19 comparing them with the  
1181 same markers described for aged individuals. The size of the circles is proportional to the  
1182 intensity of the parameter they represent.

### 1183 Tables

1184 **Table 1: Characterization of the study sample**

	Flu-Like Syndrome (n=131)	COVID-19 Mild (n=127)	COVID-19 Moderate (n=18)	COVID-19 Severe (n=33)	P value
<b>Age (years) (median; min/max)</b>	38,0 (20±90)	39,0 (20±77)	49,0 (20±65)	<b>*51,0 (31±68)</b>	<b>*p=0,147</b>
<b>Sex</b>					
Female (%)	54,9	53,5	55,5	52,3	-
Male (%)	45,0	46,4	44,4	47,6	-
<b>BMI (kg/m<sup>2</sup>) (median)</b>	26,4	26,2	35,5	29,4	p>0,05
<b>Symptoms onset (days) (median)</b>	4,0	4,0	5,0	5,0	p>0,05
<b>Comorbidities</b>					
Hypertension (%)	17,5	14,1	44,4	42,4	-
Diabetes mellitus (%)	0,7	3,1	16,6	15,1	-
Respiratory diseases (%)	10,6	11,0	0,0	6,0	-
Others (%)	10,6	12,5	5,5	18,1	-

1185  
1186 Data presented as median (min-max) and mean ( $\pm$  standard deviation). The Kruskal-Wallis and  
1187 Dunn's tests were applied. \*Corresponds to the difference found for comparison between the  
1188 other compared groups.

1189

1190

1191

1192 **Table 2: Characterization of the study sample by region**

<b>Belo Horizonte</b>	<b>Flu-Like Syndrome (n=76)</b>	<b>COVID-19 Mild (n=79)</b>	<b>COVID-19 Moderate (n=05)</b>	<b>COVID-19 Severe (n=14)</b>	<b>P value</b>
<b>Age (years) (median; min/max)</b>	41,0 (20±79)	38,0 (20±68)	51,0 (31±64)	<b>*53,0 (32±89)</b>	<b>*p=0,121</b>
<b>Sex</b>					
Female (%)	53,9	50,6	20,0	28,5	-
Male (%)	46,0	49,3	80,0	71,4	-
<b>BMI (kg/m2) (median)</b>	26,1	26,0	33,5	28,4	p>0,05
<b>Symptoms onset (days) (median)</b>	4,0	5,0	2,0	4,0	p>0,05
<b>Comorbidities</b>					
Hypertension (%)	11,8	11,3	20,0	14,2	-
Diabetes mellitus (%)	2,6	3,7	20,0	14,2	-
Respiratory diseases (%)	10,5	11,3	0,0	0,0	-
Others (%)	7,8	13,9	0,0	7,1	-
<b>Governador Valadares</b>	<b>Flu-Like Syndrome (n=44)</b>	<b>COVID-19 Mild (n=42)</b>	<b>COVID-19 Moderate (n=00)</b>	<b>COVID-19 Severe (n=03)</b>	<b>P value</b>
<b>Age (years) (median; min/max)</b>	35,0 (20±90)	39,0	-	45,0	p>0,05
<b>Sex</b>					
Female (%)	47,7	59,5	-	33,5	-
Male (%)	52,3	40,4	-	66,5	-
<b>BMI (kg/m2) (median)</b>	26,6	26,2	-	22,3	p>0,05
<b>Symptoms onset (days) (median)</b>	3,0	4,0	-	3,0	p>0,05
<b>Comorbidities</b>					
Hypertension (%)	9,0	11,9	-	33,3	-
Diabetes mellitus (%)	0,0	0,0	-	0,0	-
Respiratory diseases (%)	4,54	4,7	-	0,0	-
Others (%)	0,0	2,3	-	33,3	-
<b>São Paulo</b>	<b>Flu-Like Syndrome (n=11)</b>	<b>Covid-19 Mild (n=06)</b>	<b>Covid-19 Moderate (n=13)</b>	<b>Covid-19 Severe (n=16)</b>	<b>p value</b>
<b>Age (years) (median; min/max)</b>	40,0 (23±69)	41,5 (28±50)	48,0 (20±56)	51,0 (31±64)	p>0,05
<b>Sex</b>					
Female (%)	45,4	50,0	69,2	56,2	-
Male (%)	54,5	50,0	30,7	43,7	-
<b>BMI (kg/m2) (median)</b>	-	-	-	-	-
<b>Symptoms onset (days) (median)</b>	5,0	4,5	5,0	5,0	p>0,05
<b>Comorbidities</b>					
Hypertension (%)	9,9	0,0	38,4	37,5	-
Diabetes mellitus (%)	0,0	0,0	7,6	18,7	-
Respiratory diseases (%)	27,7	0,0	0,0	12,5	-
Others (%)	0,0	0,0	7,6	12,5	-

1193


1194 Data presented as median (min-max) and mean ( $\pm$  standard deviation). The Kruskal-Wallis and  
 1195 Dunn's tests were applied. \*Corresponds to the difference found for comparison between the  
 1196 other compared groups.

1197




1198 **Figure 1**

1199 **Figure 2**



1200 **Figure 3**

1201 **Figure 4**



1202